Sign in
Taking people in South KoreaPhase 4

Tests pioglitazone and empagliflozin together for fatty liver in type 2 diabetes

Tests two diabetes drugs together in adults with type 2 diabetes and fatty liver.

Key facts

Who runs it
Seoul National University Bundang Hospital
Where
Seongnam-si, South KoreaSee the site
Trial code
Registry title
Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes
Status
Recruiting
Phase
Phase 4
People taking part
120 people, planned
Started
1 Jan 2025
Expected to end
30 Jun 2027
Type of study
Interventional, 3 groups
Treatments tested
  • Pioglitazone 15 MG [Actos]
  • Empagliflozin 10 MG [Jardiance]
  • Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]
Record updated
25 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes that is not well controlled and with fatty liver linked to metabolic problems. It tests two diabetes drugs, pioglitazone and empagliflozin, taken together.

Age
20 years or older.
Sex
All sexes can join.
Disease stage
Type 2 diabetes with HbA1c between 7% (53 mmol/mol) and 10% (86 mmol/mol). Fatty liver seen on Fibroscan within the past 3 months, with CAP of at least 268 dB/m. At least one metabolic problem is also needed, such as large waist, high blood pressure, high triglycerides, low HDL-cholesterol, HOMA-IR of at least 2.5, or CRP of at least 2 mg/L.
Earlier treatment
Must be taking metformin alone, metformin with a sulfonylurea, metformin with a DPP-4 inhibitor, or triple therapy including metformin. The sulfonylurea will be stopped at enrolment. Diabetes or metabolic medicines must not have changed in the past 3 months. No GLP-1 receptor agonists, SGLT2 inhibitors, rosiglitazone, vitamin E or ursodeoxycholic acid in the past 3 months.
Biomarker or test result
Fibroscan with a controlled attenuation parameter (CAP) of at least 268 dB/m within the past 3 months. HbA1c between 7% (53 mmol/mol) and 10% (86 mmol/mol).

Main reasons for not taking part

  • Insulin treatment or type 1 diabetes
  • Other causes of fatty liver, such as hepatitis B, hepatitis C or alcoholic fatty liver
  • Severe liver or kidney failure, or dialysis
  • Heart failure, or cancer including bladder cancer
  • Pregnancy or planning to become pregnant

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Adults aged 20 years or older
  • Patients with inadequately controlled type 2 diabetes mellitus, defined as HbA1c between 7% and 10%, who are currently treated with either:; Combination therapy of metformin and a sulfonylurea, or; Combination therapy of metformin and a DPP-4 inhibitor, or; Metformin monotherapy, or; Triple therapy (including metformin) provided that sulfonylurea will be discontinued upon study enrollment
  • Evidence of hepatic steatosis within the past 3 months, confirmed by Fibroscan with a controlled attenuation parameter (CAP) ≥ 268 dB/m (consistent with S2 or greater [≥10% hepatocyte steatosis] according to the 2024 EASL-EASD-EASO guidelines)
  • Presence of at least one of the following metabolic abnormalities:; Waist circumference ≥90 cm for men or ≥85 cm for women; Blood pressure ≥130 mmHg systolic or ≥85 mmHg diastolic, or use of antihypertensive medication; Serum triglycerides ≥150 mg/dL or current use of lipid-lowering agents; HDL-cholesterol ≤45 mg/dL for men or ≤50 mg/dL for women; HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) ≥2.5; Serum C-reactive protein (CRP) ≥2 mg/L
  • No changes in anti-diabetic or metabolic medications within the past 3 months, unless the changes are deemed by the investigator not to affect study outcomes

Who cannot take part

  • Patients receiving insulin therapy or diagnosed with type 1 diabetes mellitus
  • Use of the following medications within the past 3 months: GLP-1 receptor agonists, SGLT2 inhibitors, rosiglitazone (TZD), vitamin E, or ursodeoxycholic acid (UDCA)
  • Use of medications known to induce hepatic steatosis, including valproic acid, estrogen, tamoxifen, amiodarone, or chloroquine
  • Presence of secondary causes of hepatic steatosis unrelated to metabolic dysfunction, such as hepatitis B, hepatitis C, or alcoholic fatty liver disease
  • Presence of hepatocellular carcinoma, active malignancy, or metastatic cancer
  • History of or active bladder cancer
  • History of heart failure or current diagnosis of heart failure
  • Presence of terminal illnesses
  • History of gallstone disease, chronic pancreatitis, or acute pancreatitis
  • Known hypersensitivity to the active ingredients or excipients of the study medications
  • History of diabetic ketoacidosis
  • Severe organ failure, defined as:; Liver failure: AST or ALT > 5 times the upper normal limit (UNL), serum albumin < 3.2 g/dL, platelet count < 60,000/µL, or Child-Pugh-Turcotte stage B or C; Renal failure: Serum creatinine ≥ 2.0 mg/dL, estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² (CKD-EPI formula), or patients with end-stage renal disease or on dialysis
  • Underweight patients (body mass index [BMI] < 18.5 kg/m²)
  • Pregnant women or women planning to become pregnant

Where in South Korea

  • Seoul National University Bundang HospitalSeongnam-si, South KoreaContact: Soo Lim DrTaking people

About the trial

What the trial wants to find out

This exploratory study will assess the efficacy of combined pioglitazone and empagliflozin therapy in improving hepatic and metabolic outcomes in patients with type 2 diabetes mellitus and metabolic dysfunction-associated fatty liver disease (MAFLD). Although each agent has shown beneficial effects individually, evidence on their combined impact on liver health is scarce. This study seeks to determine whether the combination therapy yields additive improvements in hepatic steatosis, inflammation, and fibrosis, potentially offering a new therapeutic strategy for diabetic patients with fatty liver disease.

The 3 groups in the trial

  • PioglitazoneTreatment being tested

    Pioglitazone 15mg

    Treatment: Empagliflozin 10 MG [Jardiance]

  • EmpagliflozinTreatment being tested

    Empagliflozin 10mg

    Treatment: Pioglitazone 15 MG [Actos]

  • Pioglitazone & EmpagliflozinTreatment being tested

    Pioglitazone 15mg + Empagliflozin 10mg

    Treatment: Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of Pioglitazone and Empagliflozin Combination Therapy in Type 2 Diabetes Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
Plain-language title
Tests pioglitazone and empagliflozin together for fatty liver in type 2 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
25 May 2025